BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-335@pharmaconomics
DTSTAMP:20260707T050151Z
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260630
SUMMARY:ARQT Approval — ZORYVE (roflumilast) Cream 0.3%
DESCRIPTION:A final FDA approval decision on ZORYVE (roflumilast) Cream 0.3% for Plaque Psoriasis in children (age 2+) is expected Jun 29\, 2026.\n\nPrimary source: https://www.globenewswire.com/news-release/2026/07/02/3321539/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html\n\nTrack it: https://www.pharmaconomics.com/e/335
URL:https://www.pharmaconomics.com/e/335
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ARQT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR